secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2025-02-20T23:59:59+00:00
Accession:  0000950170-25-023741
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio reports Q4 net loss of $1.40/share; Attruby launch with 1,028 scripts, EU approval triggers $75M milestone
--------------------------------------------------------------------------------

- Attruby (acoramidis) prescriptions reached 1,028 from 516 prescribers as of Feb 17; EU approval on Feb 10 triggered $75M milestone.
- Q4 2024 net loss $265.1M ($1.40 EPS); full-year net loss $535.8M ($2.88 EPS).
- Q4 revenue $5.9M including $2.9M Attruby sales; full-year revenue $221.9M driven by $207.7M from Bayer/Kyowa Kirin deals.
- Cash, cash equivalents and short-term restricted cash $681.2M at Dec 31, 2024, up from $392.6M at Dec 31, 2023.
- Three Phase 3 trials (LGMD2I, ADH1, achondroplasia) fully enrolled; last participant last visit expected 2H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000095017025023741/0000950170-25-023741-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000095017025023741/bbio-20250220.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-023741

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer